Valuation : Solid Biosciences Inc.

Market Cap 1.12B 961M 905M 826M 1.55B 105B 1.55B 10.69B 4.15B 54.12B 4.2B 4.1B 174B P/E 2026 *
-6.02x
P/E 2027 * -6.05x
Enterprise Value 823M 708M 666M 609M 1.14B 77.72B 1.14B 7.87B 3.06B 39.87B 3.09B 3.02B 128B EV / Sales 2026 *
-
EV / Sales 2027 * 85.1x
Free-Float
88.22%
Yield 2026 *
-
Yield 2027 * -
1 day-0.34%
1 week+6.04%
Current month+8.14%
1 month+20.19%
3 months+43.09%
6 months+68.73%
Current year+83.69%
1 week 9.37
Extreme 9.37
10.48
1 month 8.29
Extreme 8.29
10.48
Current year 4.92
Extreme 4.92
11.45
1 year 3.79
Extreme 3.79
11.45
3 years 1.81
Extreme 1.81
15.05
5 years 1.81
Extreme 1.81
51.3
10 years 1.81
Extreme 1.81
822.6
Manager TitleAgeSince
Chief Executive Officer 55 02/12/2022
Corporate Officer/Principal - 01/09/2014
Director of Finance/CFO 48 09/01/2023
Director TitleAgeSince
Director/Board Member 52 01/03/2013
Director/Board Member 60 01/11/2015
Director/Board Member 46 01/11/2015
Date Insider Type Main position Quantity % Market Cap. Importance
02/07/26 Exercice

Chairman

6,880 0.0070%
10/06/26 Free

Founder

77,500 0.0787%
02/04/26 Exercice

Chairman

6,882 0.0070%
Change 5-day change 1-year change 3-year change Capi.($)
-0.24%+6.04%+86.33%+191.83% 1.12B
-1.79%-3.82%+38.74%+91.90% 69.02B
-2.06%-0.18%+41.53%+88.17% 66.32B
-0.43%+6.20%-11.67%+377.40% 27.66B
+1.51%+2.18%+0.77%-14.51% 25.84B
-3.00%-2.61%+34.45%+11.39% 26.54B
-1.46%+0.42%+24.07%-18.70% 20.4B
-2.96%-16.03%+213.13%+375.00% 17.63B
-1.49%-6.69%-4.69%+539.74% 15.15B
-0.14%+8.26%+57.69%+164.68% 14.65B
Average -1.23%-0.31%+48.03%+180.69% 28.43B
Weighted average by Cap. -1.49%-0.44%+39.24%+139.24%

Financials

2026 *2027 *
Net sales - 9.96M 8.57M 8.06M 7.37M 13.78M 941M 13.82M 95.3M 36.98M 483M 37.41M 36.59M 1.55B
Net income -225M -193M -182M -166M -311M -21.2B -311M -2.15B -833M -10.88B -843M -825M -35.04B -239M -206M -194M -177M -331M -22.61B -332M -2.29B -889M -11.6B -899M -880M -37.37B
Net Debt -294M -253M -238M -218M -407M -27.77B -408M -2.81B -1.09B -14.25B -1.1B -1.08B -45.9B -270M -232M -218M -199M -373M -25.45B -374M -2.58B -1B -13.06B -1.01B -990M -42.06B
Logo Solid Biosciences Inc.
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Employees
121
Date Price Change Volume
04/09/26 $10.36 -0.62% 214,880
03/09/26 $10.42 +1.31% 728,483
02/09/26 $10.29 +4.10% 894,270
01/09/26 $9.880 +3.13% 803,305
31/08/26 $9.580 -1.94% 686,620
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
10.42USD
Average target price
18.67USD
Spread / Average Target
+79.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SLDB Stock